Fairmount Funds Management LLC bought VRDN
October 23, 2025 · Form 4 insider transaction
Fairmount Funds Management LLC bought 454,545 shares of Viridian Therapeutics, Inc. at $22.00 per share, a transaction worth $10.00M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
454,545
Price
$22.00
Total value
$10.00M
Role—
SecurityCommon Stock
Transaction codeP: Open-market purchase
Transaction dateOctober 23, 2025
Filing dateOctober 27, 2025
Shares owned after3,914,458
OwnershipIndirect
10b5-1 planNo
AmendedNo
Footnotes
Fairmount Funds Management LLC ("Fairmount") and Fairmount Healthcare Fund II GP LLC ("Fairmount GP II") have voting power and investment power over the securities held by Fairmount Healthcare Fund II LP ("Fund II"). They disclaim beneficial ownership of securities held by Fund II for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.